LATEST NEWS
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3

View Resource PDF
View Resource

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.

CONTACT US